Anti-Human Prolactin

Anti-Human Prolactin

Product No.: P283

[product_table name="All Top" skus="P283"]

- -
- -
Target
Prolactin
Product Type
Polyclonal Antibody
Alternate Names
Mammotropin, Luterotropic Hormone (LTH), Lutetropin
Applications
ELISA Cap
,
IHC
,
N
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Goat
Immunogen
Purified Recombinant Human PRL (>98%)
Endotoxin Level
<0.1 EU/µg as determined by the LAL method
Formulation
This antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.4 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.
State of Matter
Lyophilized
Storage and Handling
The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.
Country of Origin
USA
Shipping
Next Day Ambient
Applications and Recommended Usage?
Quality Tested by Leinco
ELISA Sandwich: This antibody is useful as the capture antibody in a sandwich ELISA. The suggested coating concentration is 0.2-0.8 µg/ml. A suitable detection antibody is PN:P294 at a concentration of approximately 0.1-0.4 µg/ml. A suggested standard for this assay is PN:P168.
Western Blotting: To detect Human PRL this polyclonal antibody can be used at a concentration of 0.25 µg/ml. This polyclonal antibody should be used in conjunction with compatible second-step reagents such as PN:G505 and a chromogenic substrate such as PN:T343. The detection limit for Human PRL is 5 ng/lane under either reducing or non-reducing conditions. The sensitivity of detection may increase up to 50 fold when a chemiluminescent substrate is used. A suitable Western blotting control is PN:P168.
Additional Applications Reported In Literature ?
Neutralization: This antibody is useful for neutralization of Human PRL bioactivity. The antibody dose required to neutralize 50% (ND50) of the biological activity of Human PRL (at 0.5 ng/ml) is 0.02 - 0.05 µg/ml.
Immunohistochemistry: Suitable for use at concentration of 1-15 µg/mL.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Goat Anti-Human Prolactin (PRL) recognizes Human PRL. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.
Background
Prolactin (PRL) or Luteotropic hormone (LTH) is best known as the pituitary modulator of lactation and reproduction.1 Prolactin is a multifaceted hormone that is capable of modulating hundreds of physiological processes in adult vertebrates.2 PRL promotes proliferation, survival and migration of cancer cells acting via the prolactin receptor (PRLR).3 It also modulates maternal behavior and mediates hypothalamic pituitary adrenal axis inhibition during lactation via PRL receptors in the brain.4 Prolactin also has a number of other effects including contributing to surfactant synthesis of the fetal lungs at the end of the pregnancy and immune tolerance of the fetus by the maternal organism during pregnancy. It also decreases normal levels of sex hormones — estrogen in women and testosterone in men.5
PubMed
NCBI Gene Bank ID

References & Citations

1. Paus, R. et al. (2012) Arch Dermatol Res. 304(2):115-8.
2. Zhu, Y. et al. (2008) Comp Biochem Physiol C Toxicol Pharmacol. 148(4):370-80.
3. Panina, S. et al. (2009) J Endocrinol. 201(1):115-28.
4. Neuwmann, ID. et al. (2009) Endocrinology. 150(4):1841-9.
5. Molitch MD., ME. (2005) Mayo Clinic Proceedings 80(8):1050-1057
6. Gout, PW. et al. (1980) Cancer Research 40:2433-36.
Elisa Sandwich Protocol
IHC
N
General Western Blot Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.